RVS physicians have served as principal investigators in many clinical trials over the past 30 years and continue their ongoing commitment to improving the quality and safety of retinal treatments. We strongly believe that our patients and community should have access to cutting-edge medical care through offering the option of clinical research. We partner with the National Institute of Health, the National Eye Institute, and some of the nation's top pharmaceutical companies in our quest for improving patient care and quality of life. All of our trials are sponsored; so eligible participants will not incur additional costs. Contact us at (315)-445-8166 if you are interested in finding out more information about possible participation in our clinical research.

 

Active Clinical Trials:

Chengdu KHB-1802 – A Multicenter, Double-Masked, Randomized, Dose Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration


Tenaya – A Phase III, multicenter, Active Comparator-Controlled study to evaluate the efficacy and safety of Faricimab in patients with neovascular age-related macular degeneration

 

Yosemite – A Phase III, multicenter, Active Comparator-Controlled study to evaluate the efficacy and safety of RO6867461 in patient with Diabetic Macular Edema

 

Xplore – A Phase III Double-Blind, parallel group to compare the efficacy and safety of Xlucane versus Lucentis in Patients with Neovascular Age-Related Macular Degeneration

 

Novartis Merlin RTH258 CRTH258AUS04 – Phase 3a study to assess safety and efficacy of brolucizumab 6 mg q4 weeks compared aflibercept 2 mg q4 weeks in patients with nAMD

 

DRCR Protocol AG – Clinical trial assessing the effects of Pneumatic Vitreolysis on Vitreomacular Traction

 

DRCR Protocol AH – Single arm assessing the effects of Pneumatic Vitreolysis on Macular Hole

 


Active Closed Clinical Trials:
Genentech Archway GR40548 – Active-comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in patients with nAMD

 

OPHTHOTECH OPH2003b – A Phase 2b randomized, double-masked, controlled trial to assess the safety and efficacy of Intravitreous administration of Zimura (Andti-C5 Aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration


Samsung SB11-G31-AMD – A phase III Randomized, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB11 (proposed ranibizumab biosimilar) and Lucentis in Subjects with Neovascular Age-related Macular Degeneration

 

DRCR Protocol TX – Phase II combination steroid and anti-VEGF for persistent DME

 

DRCR Protocol V – Treatment for CI-DME in eyes with very good VA study

 

DRCR Protocol W – Anti-VEGF treatment for prevention of PDR/DME

 

DRCR Protocol AA – Compare effectiveness study of intravitreal Aflibercept, Bevacizumab, and Ranibizumab for diabetic macular edema

 


Closed Clinical Trials:

Iconic – A phase 2 Randomized, Open –Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients with Choroidal neovascularization Secondary to Age-related Macular Degeneration

 

Allergan Sequoia 150998-006 – Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration

 

Novartis RTH258/Brolucizumab – A 24-week, double masked, multicenter, two-arm extension study to collect safety and efficacy data on brolucizumab 6mg drug product intended for commercialization in patient with neovascular age-related macular degeneration who have completed the CRTH258A2301 study

 

Aerpio AKB-9778-CI-5001 – Phase 2 double masked, placebo-controlled study to assess the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice dally for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy

 

Allergan Maple 1771-201-008 – Evaluation of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration

 

Clearside TOPAZ CLS1003-302 – A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in combination with an intravitreal anti-veg agent in subjects with retinal vein occlusion

 

Opthea OPT302-1002 – A dose- ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)

 

Genentech Chroma GX29176 – A study investigating the efficacy and safety of Lampalizumab intravitreal injections in participants with geographic atrophy secondary to age-related macular degeneration

 

Genentech Omaspect GX30191 – A long-term safety of Lampalizumab intravitreal injections in participants with geographic atrophy secondary to age-related macular degeneration

 

Allegro Pacific – A clinical trial designed to evaluate the safety and efficacy study of Luminate in inducing PVD (Posterior Vitreous Detachment) in Non-proliferative diabetic retinopathy

 

Ophthotech OPH1004 – A phase 3 randomized, double masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration

 

Ophthotech OPH1003 – A phase 3 safety and efficacy study of Fovista (E10030) intravitreous administration in combination with Lucentis compared to Lucentis monotherapy

 

Regeneron ONYX 1517 – Anti-angiOpeitin 2 plus anti-vascular eNdothelial growth factor as a therapy for neovascular age related macular degeneration: evaluation of a fixed combination intravitreal injection (ONYX)

 

Ohr-1601 Mako – Efficacy and safety of Squalamine Lactate eye drops in subjects with neovascular (Wet) age-related macular degeneration (AMD)

 

Alcon RTH258-C001A HAWK – A two year, randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of TRH258 versus Aflibercept in subjects with neovascular age-related macular degeneration

 

Iconic Emerge – Study evaluating intravitreal hl-con1 in patients with choroidal neovascularization secondary to age-related macular degeneration

 

Regeneron VEGF Trap 0605 – Randomized Double Masked Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular AMD

 

VAM Study – Phase 3 Safety and Efficacy Study for Visudyne for Age Related Macular Degeneration
VERITAS – A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

Genentech – Phase 3b Safety Study for Ranibizumab for Age Related Macular (SAILOR)

Allergan – SIRIUS siRNA for Age Related Macular Degeneration

 

Regeneron VEGF Trap – Randomized Double Masked Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Branch Vein Occlusions.

 

National Institute of Health – Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study

 

Diabetic Retinopathy
Diabetic Retinopathy Clinical Research Network – National Institute of Health
Protocol A – A pilot study of laser photocoagulation for DME
Protocol B – A randomized trial comparing IVT and laser for DME
Protocol C – Temporal variation in OCT of retinal thickening measurements in DME
Protocol D – Evaluation of vitrectomy for ME
Protocol E – Pilot study of peribulbar triamcinolone acetonide
Protocol F – Observational study of the development of DME following scatter laser Photocoagulation
Protocol G – Subclinical DME study
Protocol K – Course of response to focal photocoagulation for DME
Protocol I – Laser-Ranibizumab-Triamcinolone for DME
Protocol J – Laser-Ranibizumab-Triamcinolone for DME + PRP
Protocol O – Comparison of TD & SD OCT
Protocol P – Cataract Surgery with Center-Involved DME
Protocol N – Intravitreal Ranibizumab for Vitreous Hge
Protocol R – Phase II non-Central DME NSAID
Protocol S – Prompt panretinal photocoagulation versus intravitreal Ranibizumab with deferred panretinal photocoagulation for PDR

 

Bristol-Myers-Squibb – Pilot Study of Irbesartain in the Hypertensive Type II Diabetic


Retinopathy of Prematurity
National Institute of Health
Cryotherapy for Retinopathy of Prematurity Study (CRYO-ROP)
Early Treatment for ROP (ETROP)

 

Vitreous Hemorrhage
ISTA Pharmaceuticals – Phase 3 Safety and Efficacy Study of Vitrase for Vitreous Hemorrhage

 

Other
United Biosource – VFQ Validation Study

Locations & Directions

 

Syracuse

 

Watertown

 

Binghamton

 

Email Us

Do NOT Send Protected Health Information via Email.

Nondiscrimination policy